Dose of Discovery

It may seem obvious, but not all drugs are manufacturable. Getting an exciting new treatment from the lab to patients is only possible if the molecule or substance itself is scalable.  In this episode of Dose of Discovery , hosts Søren and AJ speak to Cheng Yi Chen, chief technology officer at Asymchem, about the chemistry, scaling up, and decision making behind moving a drug from clinical tr...

In this episode of Dose of Discovery , hosts Søren and AJ speak to physician-scientist Stanley Crooke, CEO of the nonprofit n-Lorem Foundation, about how antisense oligonucleotide (ASO) technology has evolved into a revolutionary therapeutic modality. Their conversation explores Stan's expansive career journey, from his early days building cancer programs at Bristol Labs and SmithKline to his bold...

Welcome to Dose of Discovery : a dose of breakthrough medical discoveries, delivered with your morning coffee. (Coffee not included.) In this first episode, hosts AJ and Søren speak to Julia Alterman, assistant professor at the RNA Therapeutics Institute at UMass Chan Medical School, about how siRNA technology has evolved from a useful laboratory research tool into a promising therapeutic modality...

Dose of Discovery is a monthly science podcast about the people, ideas, and challenges shaping modern biomedicine. Tune in as hosts Søren and AJ have thoughtful, accessible conversations with leading scientists about complex subjects, following emerging therapeutics as they move from research to real-world impact. Dose of Discovery — BioXconomy ’s flagship podcast — is for biotech professionals, r...